Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial

por Fitchett, David, Inzucchi, Silvio E., Cannon, Christopher P., McGuire, Darren K., Scirica, Benjamin M., Johansen, Odd Erik, Sambevski, Steven, Kaspers, Stefan, Pfarr, Egon, George, Jyothis T., Zinman, Bernard
Publicado 2019

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial

por Volkmann, Elizabeth R, Kreuter, Michael, Hoffmann-Vold, Anna M, Wijsenbeek, Marlies , Smith, Vanessa, Khanna, Dinesh, Denton, Christopher P, Wuyts, Wim A  , Miede, Corinna, Alves, Margarida, Sambevski, Steven, Allanore, Yannick 
Publicado 2022

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

por Khanna, Dinesh, Maher, Toby M, Volkmann, Elizabeth R, Allanore, Yannick, Smith, Vanessa, Assassi, Shervin, Kreuter, Michael, Hoffmann-Vold, Anna-Maria, Kuwana, Masataka, Stock, Christian, Alves, Margarida, Sambevski, Steven, Denton, Christopher P
Publicado 2023